In agreement with previous findings that taxane treatment can induce nuclear localization of FOXO proteins in ovarian, breast and prostate cancer cells 50-52, combination of GSK126 and DTX results in a significant increase in FOXO1 protein expression in the nucleus and growth inhibition in PTEN-negative cells both in vitro and in vivo in comparison to each single treatment alone. The gene discussed is FOXO1; the disease is prostate cancer.